Aurora Cannabis leans into medical cannabis sales in Europe and Australia, betting that tighter rules and growing acceptance help established players win share and improve profitability. The upside looks tied to staying ahead on compliance and keeping costs in check as competition, regulation shifts, and weaker side businesses could pressure results.Read more
Aurora Cannabis is pushing deeper into international medical markets, but shifting rules in Europe and tougher competition could slow growth and squeeze profits. See why rising costs and the pace of medical adoption may matter as much as new country launches.Read more
Key Takeaways Aurora's regulatory expertise, market relationships, and product innovation position it for accelerated growth and dominant market share as global legalization expands. Strong financial health and operational advantages enable aggressive acquisitions, premium product leadership, and significant margin improvements across consolidating international markets.Read more
Aurora Cannabis Inc., together with its subsidiaries, engages in the production, distribution, and sale of cannabis products in Canada and internationally. The company offers pharmaceutical-grade cannabis products; and medical and consumer cannabis products. It also provides harvested cannabis, trim, cannabis oils, capsules, edibles, vaporizers, dried and fresh cannabis, cannabis plants, cannabis seeds, edible cannabis, cannabis extracts, flowers, vapes / inhalable extracts, edibles / pastilles, concentrates, and cannabis topicals; and patient counseling and outreach services. Its brand portfolio includes Aurora, Being, CanniMed, CraftPlant, Daily Special, Drift, Greybeard, IndiMed, MedReleaf, Pedanios, San Raf, Tasty’s, Whistler, and WMMC. Aurora Cannabis Inc. was founded in 2013 and is headquartered in Edmonton, Canada.
